Genzyme Receives "Complete Response," Warning Letters For Lumizyme
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The hits just keep on coming for Genzyme. On a March 2 call with investors, the firm had to announce not just a "complete response" letter for its 2000-liter scale-up of Myozyme (which will be called Lumizyme for the larger production scale), but also that its Allston Landing manufacturing site had received a 483 report from FDA and a subsequent warning letter
You may also be interested in...
Rationing Of Genzyme’s Myozyme In Europe Likely Through April Due To Supply Constraints
Until approval of the larger 4000 L bioreactor for the Pompe Disease product, EMEA recommends priority access for infants, children and adolescents.
FDA Agrees To Accelerated Approval For Myozyme Scale-Up, Genzyme Says
The 2,000L version of Myozyme on track for approval with a post-market confirmatory trial in February; user fee date extended while FDA reviews REMS submission.
Pending Approvals Hold Major Implications For Myozyme Growth
Genzyme reports increasing sales for Pompe disease drug, but upcoming EU and FDA decisions could spur or stifle product’s growth.